Home LiteratureArticle Details
PMID: 10362351 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.

Oncogene ·Vol. 18 ·No. 22 ·1999-06-03 ·Pages 3309-15

Mantovani F, Banks L

Abstract

The E6 proteins derived from tumour associated papillomavirus types target the cellular tumour suppressor protein p53 for ubiquitin mediated degradation. In cell lines derived from cervical tumours the p53 protein is present in very low amounts, but it can be activated by appropriate DNA damaging agents, indicating that functional p53 is present within these lines. Recent studies have also shown that different polymorphic forms of the p53 protein are differentially susceptible to E6 mediated degradation. Therefore we have been interested in analysing the effects of different HPV E6 proteins upon p53 levels in a variety of cervical tumour derived cell lines. We show that inhibition of E6 mediated degradation of p53 frequently results in increased levels of p53 expression. However, there are notable exceptions to this where increased p53 levels are only obtained following DNA damage and proteasome inhibition. We also show in E6 expressing cells, that as well as p53 being targeted for degradation, the localization of p53 to the nucleus is also inhibited, consistent with previous observations which indicate that degradation of p53 is not essential for E6 mediated inhibition of p53 function. These results have important implications for any potential therapies which might aim to block E6 mediated degradation of p53.

MeSH Terms
Acetylcysteine/analogs & derivatives,pharmacology Adenocarcinoma/drug therapy,genetics Animals Antibiotics, Antineoplastic/pharmacology Breast Neoplasms/drug therapy,genetics Carcinoma/drug therapy,genetics,virology Cell Nucleus/metabolism Cysteine Proteinase Inhibitors/pharmacology DNA Damage/drug effects DNA-Binding Proteins Female Fibrosarcoma/drug therapy,genetics Humans Leupeptins/pharmacology Mitomycin/pharmacology Oncogene Proteins, Viral/metabolism Papillomaviridae/metabolism Polymorphism, Genetic Repressor Proteins Tumor Cells, Cultured/drug effects,metabolism,virology Tumor Suppressor Protein p53/drug effects,genetics,metabolism Uterine Cervical Neoplasms/drug therapy,genetics,virology
Chemicals
Antibiotics, Antineoplastic Cysteine Proteinase Inhibitors DNA-Binding Proteins E6 protein, Human papillomavirus type 16 E6 protein, Human papillomavirus type 18 Leupeptins Oncogene Proteins, Viral Repressor Proteins Tumor Suppressor Protein p53 acetylleucyl-leucyl-norleucinal lactacystin Mitomycin Acetylcysteine
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Mantovani F
International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
Banks L
Article Info
Journal
Oncogene
Abbr.
Oncogene
ISSN
0950-9232
Published
1999-06-03
Pages
3309-15
Language
English
Region
England
NLM ID
8711562
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com